JP2020529834A5 - - Google Patents

Download PDF

Info

Publication number
JP2020529834A5
JP2020529834A5 JP2019571593A JP2019571593A JP2020529834A5 JP 2020529834 A5 JP2020529834 A5 JP 2020529834A5 JP 2019571593 A JP2019571593 A JP 2019571593A JP 2019571593 A JP2019571593 A JP 2019571593A JP 2020529834 A5 JP2020529834 A5 JP 2020529834A5
Authority
JP
Japan
Prior art keywords
modified human
genetically modified
cell
interest
exogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019571593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020529834A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039740 external-priority patent/WO2019005957A1/en
Publication of JP2020529834A publication Critical patent/JP2020529834A/ja
Publication of JP2020529834A5 publication Critical patent/JP2020529834A5/ja
Priority to JP2022022074A priority Critical patent/JP2022078103A/ja
Priority to JP2023133418A priority patent/JP2023175699A/ja
Priority to JP2025026102A priority patent/JP2025102755A/ja
Priority to JP2025172936A priority patent/JP2026027250A/ja
Pending legal-status Critical Current

Links

JP2019571593A 2017-06-30 2018-06-27 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 Pending JP2020529834A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022022074A JP2022078103A (ja) 2017-06-30 2022-02-16 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2023133418A JP2023175699A (ja) 2017-06-30 2023-08-18 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025026102A JP2025102755A (ja) 2017-06-30 2025-02-20 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025172936A JP2026027250A (ja) 2017-06-30 2025-10-14 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762527845P 2017-06-30 2017-06-30
US62/527,845 2017-06-30
US201762579473P 2017-10-31 2017-10-31
US62/579,473 2017-10-31
PCT/US2018/039740 WO2019005957A1 (en) 2017-06-30 2018-06-27 GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022022074A Division JP2022078103A (ja) 2017-06-30 2022-02-16 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞

Publications (2)

Publication Number Publication Date
JP2020529834A JP2020529834A (ja) 2020-10-15
JP2020529834A5 true JP2020529834A5 (cg-RX-API-DMAC7.html) 2021-08-05

Family

ID=63103995

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019571593A Pending JP2020529834A (ja) 2017-06-30 2018-06-27 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2022022074A Pending JP2022078103A (ja) 2017-06-30 2022-02-16 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2023133418A Withdrawn JP2023175699A (ja) 2017-06-30 2023-08-18 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025026102A Pending JP2025102755A (ja) 2017-06-30 2025-02-20 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025172936A Pending JP2026027250A (ja) 2017-06-30 2025-10-14 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022022074A Pending JP2022078103A (ja) 2017-06-30 2022-02-16 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2023133418A Withdrawn JP2023175699A (ja) 2017-06-30 2023-08-18 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025026102A Pending JP2025102755A (ja) 2017-06-30 2025-02-20 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞
JP2025172936A Pending JP2026027250A (ja) 2017-06-30 2025-10-14 T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞

Country Status (7)

Country Link
US (2) US11053484B2 (cg-RX-API-DMAC7.html)
EP (2) EP4775669A2 (cg-RX-API-DMAC7.html)
JP (5) JP2020529834A (cg-RX-API-DMAC7.html)
AU (3) AU2018292526A1 (cg-RX-API-DMAC7.html)
CA (1) CA3068465A1 (cg-RX-API-DMAC7.html)
ES (1) ES3067983T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019005957A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
EP4775669A2 (en) * 2017-06-30 2026-07-15 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
KR102617818B1 (ko) 2018-04-12 2023-12-27 프리시젼 바이오사이언시스 인코포레이티드 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
MX2021011782A (es) * 2019-03-27 2021-12-10 Res Inst Nationwide Childrens Hospital Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav.
CN114026228A (zh) 2019-05-07 2022-02-08 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
US20220411479A1 (en) * 2019-10-30 2022-12-29 Precision Biosciences, Inc. Cd20 chimeric antigen receptors and methods of use for immunotherapy
EP4110356A4 (en) * 2020-02-28 2024-03-27 Wisconsin Alumni Research Foundation NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING
GB202005184D0 (en) * 2020-04-08 2020-05-20 Autolus Ltd Method
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
WO2022132756A1 (en) * 2020-12-14 2022-06-23 Emendobio Inc. Biallelic knockout of trac
AU2022368911A1 (en) 2021-10-19 2024-05-30 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
EP4493697A4 (en) * 2022-03-16 2026-06-10 Univ Minnesota GENETICALLY MODIFIED T LYMPHOCYTES FOR CELL THERAPY
WO2025165787A1 (en) * 2024-02-01 2025-08-07 The Board Of Trustees Of The Leland Stanford Junior University Touchless selection of gene modified cell therapies through trac intron knockins

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2008102199A1 (en) 2007-02-20 2008-08-28 Cellectis Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
EP2329017A2 (en) 2008-08-04 2011-06-08 Cellectis Novel method to generate meganucleases with altered characteristics
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
EP3683319A1 (en) 2011-06-01 2020-07-22 Precision Biosciences, Inc. Methods and products for producing engineered mammalian cell lines with amplified transgenes
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
KR20140019635A (ko) 2012-08-06 2014-02-17 엘지이노텍 주식회사 발광 소자 및 발광 소자 패키지
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
CA2913872C (en) 2013-05-31 2022-01-18 Cellectis A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof
CA2913871C (en) 2013-05-31 2021-07-13 Cellectis A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof
EP3058072B1 (en) 2013-10-17 2021-05-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
AU2015229299A1 (en) 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
WO2015167766A1 (en) 2014-04-29 2015-11-05 Seattle Children's Hospital (dba Seattle Children's Research Institute) Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
US20160081314A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
BR112017020750A2 (en) * 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
US20190017075A1 (en) 2015-12-23 2019-01-17 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
US20190241910A1 (en) 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
KR102614675B1 (ko) 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
EP4775669A2 (en) * 2017-06-30 2026-07-15 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
KR102617818B1 (ko) 2018-04-12 2023-12-27 프리시젼 바이오사이언시스 인코포레이티드 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제

Similar Documents

Publication Publication Date Title
JP7461445B2 (ja) Hla-cw8拘束性の変異krasを認識するt細胞受容体
Atsavapranee et al. Delivery technologies for T cell gene editing: applications in cancer immunotherapy
Miliotou et al. CAR T-cell therapy: a new era in cancer immunotherapy
Tichet et al. Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages
Buechler et al. Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer
Brightman et al. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy
Xi et al. Genetically engineered pigs for xenotransplantation: Hopes and challenges
Zeng et al. Exhausted T cells and epigenetic status
AU2016427822B2 (en) Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene
CN110612446B (zh) 分离新抗原-特异性t细胞受体序列的方法
JP2019511236A5 (cg-RX-API-DMAC7.html)
IL299249B2 (en) Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
Chudnovskiy et al. Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response
FI3599251T3 (fi) Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen
JP2021521849A5 (cg-RX-API-DMAC7.html)
JP2021518160A5 (cg-RX-API-DMAC7.html)
JP2018510657A5 (cg-RX-API-DMAC7.html)
Keith et al. Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa
CA3186620A1 (en) Methods and compositions for editing the b2m locus in b cells
JP2022524509A (ja) Cd40lの組成と調整可能な制御のための方法
Fesnak et al. Clinical development and manufacture of chimeric antigen receptor T cells and the role of leukapheresis
Zhou et al. Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes
Gerbitz et al. Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice
Özdemir Role of immune cells in the tumor microenvironment
Helm et al. Targeting c-MYC with T-cells